A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL

Blood

Volumn 96, Issue 12, 2000, Pages 3887-3893

  DiMartino, J F ^a   Miller, T ^a   Ayton, P M ^a   Landewe, T ^a   Hess, J L ^a   Cleary, M L ^a   Shilatifard, A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; ELONGATION FACTOR; ELONGATION FACTOR ELL; GENE PRODUCT; HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN HOXA7; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL IMMORTALIZATION; CELL NUCLEUS INCLUSION BODY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMBRYO; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; LEUKEMOGENESIS; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; TARGET CELL; TRANSCRIPTION REGULATION;

EID: 0034548830     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.12.3887     Document Type: Article

References (26)

1. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia
2. Cloning of several MLL/MEN chimeric cDNAs in myeloid leukemia with t(11;19)(q23;p13.1) translocation
3. Secondary acute leukemia and myelodysplastic syndrome with 11 q23 abnormalities
4. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II
5. HRX involvement in de novo and secondary leukemias with diverse chromosome 11 q23 abnormalities
6. Derivative chromosomes of 11q23 translocations in hematologic malignancies
7. The der 11 chromosome contains the critical breakpoint junction in the 4;11, 9;11, and 11;19 translocations in acute leukemia
8. MLL rearrangements in human malignancies: Lessons from clinical and biological studies
9. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells
10. An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes
11. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL
12. HRX DNA binding motifs and ENL transcriptional transactivation are essential requirements for the oncogenic capacity of the HRX-ENL fusion oncoprotein
13. An RNA polymerase II elongation factor encoded by the human ELL gene
14. Structure and function of RNA polymerase II elongation factor ELL: Identification of two overlapping ELL functional domains that govern its interaction with polymerase and the ternary elongation complex
15. ELL2, a new member of an ELL family or RNA polymerase II elongations factors
16. The HRX proto-oncogene product is widely expressed in human tissues and localizes to nuclear structures
17. Nuclear punctate distribution of ALL-1 is conferred by distinct elements at the N terminus of the protein
18. Chimeric MLL products with a Ras binding cytoplasmic protein AF6 involved in t(6;11) (q27;q23) leukemia localize in the nucleus
19. Efficient selection for high-expression transfectants with a novel eukaryotic vector
20. Two distinct portions of LTG19/ENL at 19p13 are involved in t(11;19) leukemia
21. Production of high-titer helper-free retroviruses by transient transfection
22. Versatile retroviral vectors for potential use in gene therapy
23. The leukemogenic fusion of MLL with ENL creates a novel transcriptional transactivator
24. Leukemic transformation of murine myeloid progenitors by retroviral transduction of MLL-ELL
25. ENL, the gene fused with HRX in t(11;19) leukemias, encodes a nuclear protein with transcriptional activation potential in lymphoid and myeloid cells
26. PHD: Predicting one-dimensional protein structure by profile-based neural networks